Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes

Jeremiah P. Depta; Deepak L. Bhatt

doi:10.1160/TH10-05-0332

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 104(04): 657-663
DOI: 10.1160/TH10-05-0332

Clinical Focus

Schattauer GmbH

Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes

Jeremiah P. Depta

¹Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

,

Deepak L. Bhatt

²VA Boston Healthcare System, Brigham and Women‘s Hospital, Harvard Medical School, Boston, Massachusetts, USA

References
1 Miyasaka Y, Barnes ME, Gersh BJ. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
2 Lloyd-Jones D, Adams RJ, Brown TM. et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-e215.
3 Goto S, Bhatt DL, Rother J. et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008; 156: 855-863e2.
4 Feinberg WM, Blackshear JL, Laupacis A. et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-473.
5 Fuster V, Moreno PR, Fayad ZA. et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46: 937-954.
6 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155-166.
7 Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002; 106: 136-140.
8 Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41: 37S-42S.
9 Boos CJ, Lip GY. The role of inflammation in atrial fibrillation. Int J Clin Pract 2005; 59: 870-872.
10 Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 2006; 27: 136-149.
11 Thambidorai SK, Parakh K, Martin DO. et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94: 805-807.
12 Conway DS, Buggins P, Hughes E. et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148: 462-466.
13 Conway DS, Buggins P, Hughes E. et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43: 2075-2082.
14 Roldan V, Marin F, Blann AD. et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24: 1373-1380.
15 Depta JP, Bhatt DL. Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. Am J Cardiovasc Drugs 2008; 8: 91-112.
16 Becker RC. Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. Am Heart J 2005; 149: S2-8.
17 Krishnamoorthy S, Lim SH, Lip GY. Assessment of endothelial (dys)function in atrial fibrillation. Ann Med 2009; 41: 576-590.
18 Li-Saw-Hee FL, Blann AD, Gurney D. et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001; 22: 1741-1747.
19 Marin F, Roldan V, Climent VE. et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart 2004; 90: 1162-1166.
20 Goto S, Sakai H, Goto M. et al. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999; 99: 608-613.
21 Sakai H, Goto S, Kim JY. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost 2000; 84: 204-209.
22 Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2: 15-28.
23 Kamath S, Chin BS, Blann AD. et al. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinol 2002; 13: 627-636.
24 Choudhury A, Chung I, Blann A. et al. Platelet adhesion in atrial fibrillation. Thromb Res 2007; 120: 623-629.
25 Sohara H, Amitani S, Kurose M. et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106-112.
26 Choudhury A, Chung I, Blann AD. et al. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest 2007; 131: 809-815.
27 Azzam H, Zagloul M. Elevated platelet microparticle levels in valvular atrial fibrillation. Hematol 2009; 14: 357-360.
28 Duygu H, Barisik V, Kurt H. et al. Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation. Europace 2008; 10: 210-214.
29 Becker RC. Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. J Thromb Thrombolysis 2005; 19: 71-75.
30 Stritzke J, Markus MR, Duderstadt S. et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/ KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. J Am Coll Cardiol 2009; 54: 1982-1989.
31 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370-2375.
32 Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-1932.
33 Wanahita N, Messerli FH, Bangalore S. et al. Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J 2008; 155: 310-315.
34 Tedrow UB, Conen D, Ridker PM. et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation: The WHS (Women’s Health Study). J Am Coll Cardiol 2010; 55: 2319-2327.
35 Bhatt DL, Steg PG, Ohman EM. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 2006; 295: 180-189.
36 Steg PG, Bhatt DL, Wilson PW. et al. One-year cardiovascular event rates in out-patients with atherothrombosis. J Am Med Assoc 2007; 297: 1197-1206.
37 Singer DE, Albers GW, Dalen JE. et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S-592S.
38 Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130: 1823-1827.
39 Nieuwlaat R, Capucci A, Lip GY. et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026.
40 Depta JP, Cannon CP, Fonarow GC. et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol 2009; 104: 1171-1178.
41 Tay KH, Lane DA, Lip GY. Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin?. Thromb Haemost 2008; 100: 955-957.
42 Kakar P, Lane D, Lip GY. Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. Chest 2006; 130: 1296-1299.
43 Somme D, Corvol A, Lazarovici C. et al. Clinical Usefulness in Geriatrics patients of Combining the CHADS2 and HEMORR2HAGES Scores for Guiding Anti-thrombotic Prophylaxis in Atrial Fibrillation. A preliminary study. Aging Clin Exp Res. 2009 Epub ahead of print.
44 Hylek EM, Evans-Molina C, Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
45 Levi M, Hovingh K. Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Thromb Haemost 2008; 100: 1047-1051.
46 Gladstone DJ, Bui E, Fang J. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-240.
47 Singer DE, Chang Y, Fang MC. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
48 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
49 Gage BF, van Walraven C, Pearce L. et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-2292.
50 Connolly S, Pogue J, Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
51 Connolly SJ, Pogue J, Eikelboom J. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
52 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
53 Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost 2008; 100: 11-13.
54 Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?. Thromb Haemost 2010; 104: 45-48.
55 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683-685.
56 Healey JS, Hart RG, Pogue J. et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke 2008; 39: 1482-1486.
57 Gorin L, Fauchier L, Nonin E. et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010; 103: 833-840.
58 Hylek EM, D’Antonio J, Evans-Molina C. et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075-1080.
59 Pradhan AA, Levine MA. Warfarin use in atrial fibrillation: A random sample survey of family physician beliefs and preferences. Can J Clin Pharmacol 2002; 9: 199-202.
60 Gage BF, Boechler M, Doggette AL. et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822-827.
61 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
62 Pengo V, Cucchini U, Denas G. et al. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. Thromb Haemost 2010; 103: 442-449.
63 Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
64 Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother 2008; 42: 523-532.
65 Man-Son-Hing M, Nichol G, Lau A. et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-685.
66 Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078.
67 Rubboli A, Halperin JL. Pro: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions‘. Thromb Haemost 2008; 100: 752-753.
68 Roldán V, Marín F. Contra: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions‘. Not for everybody. Thromb Haemost 2008; 100: 754-755.
69 Anderson JL, Adams CD, Antman EM. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007; 50: e1-e157.
70 Lip GY, Huber K, Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
71 Holmes DR, Reddy VY, Turi ZG. et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542.
72 Wrigley BJ, Lip GY. Can the WATCHMAN device truly PROTECT from stroke in atrial fibrillation?. Lancet Neurol 2009; 8: 877-878.
73 Eikelboom JW, Weitz JI. Another oral thrombin inhibitor for stroke prevention-in atrial fibrillation?. Thromb Haemost 2010; 103: 481-483.
74 Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010; 121: 1523-1532.
75 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 36: 1139-1151.
76 Randomized dabigatran etexilate dose finding study with acute coronary syndromes post index event with additional risk factors for cardiovascular complication also receiving aspirin and clopidogrel: RE-DEEM. Presented at the 82^nd Annual Scientific Sessions of the American heart Association; 2009 Nov 14–18; Orlando, FL.
77 Lip GY, Rasmussen LH, Olsson SB. et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009; 30: 2897-2907.
78 Olsson SB, Rasmussen LH, Tveit A. et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010; 103: 604-612.
79 Clinicaltrials.gov.. A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation (ARISTOTLE). Available at: http://clinicaltrials.gov/ct2/show/NCT00412984?term=apixaban&rank=7. Accessed May 20, 2010.
80 Clinicaltrials.gov.. Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial (AVERROES). Available at: http://clinicaltrials.gov/ct2/show/NCT00496769. Accessed May 20, 2010.
81 Alexander JH, Becker RC, Bhatt DL. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.
82 Clinicaltrials.gov.. Apixaban for Prevention of Acute Ischemic Events – 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome (APPRAISE-2). Available at: http://clinicaltrials.gov/ct2/show/NCT00831441?term=apixaban&rank=16. Accessed May 20, 2010.
83 Clinicaltrials.gov.. A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin In Subjects With Atrial Fibrillation – Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48). Available at: http://clinicaltrials.gov/ct2/show/NCT00781391. Accessed May 20, 2010.
84 ROCKET AF Study Investigators.. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-347.e1.
85 Mega JL, Braunwald E, Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
86 Clinicaltrials.gov.. A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome. Available at: http://clinical-trials.gov/ct2/show/NCT00809965?term=Rivaroxaban&rank=9. Accessed May 29, 2010.
87 Clinicaltrials.gov.. A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes. Available at: http://clinicaltrials.gov/ct2/show/NCT00677053?term=TAK-442&rank=1. Accessed May 29, 2010.
88 Rajagopal V, Bhatt DL. Factor Xa inhibitors is acute coronary syndromes: moving from mythology to reality. J Thromb Haemost 2005; 3: 436-438.